A stock that scores a perfect 10 should be on every investor’s list of stocks to buy. Any company that receives full marks on quality, value, or growth are stocks I’d considering a perfect 10. For this article, I’m using StockRover’s stock screening tool, which screens for such qualities among a very large basket of…

Because Covid-19 has dominated the news cycle for almost two years, many investors have ignored drug stocks outside of that domain. Betting on vaccine suppliers like Moderna (NASDAQ:MRNA) or BioNTech (NASDAQ:BNTX) has paid off — those stocks more than tripled at their peak. Since August, buying interest in these stocks has waned. The drop in…

In the 1980s, the field of genetics surged in popularity. At the time, I’m sure there were many articles promising investors that genetics stocks were on the cusp of spectacular gains. Investors who were looking for short-term payoffs then were disappointed, but now, gene editing stocks look far more promising. Researching the genetic origin behind…

Healthcare stocks are once again in the spotlight as the delta variant rides a new wave of coronavirus infections across the globe. As countries batten down the hatches again, it’s not surprising to see investors once again turn their attention towards the healthcare industry. With that in mind, let’s take a look at the healthcare…

It has been a rocky few weeks for the stock market amid concerns that a resurgence in Covid-19 cases would slow economic growth. Moreover, gold prices have also risen in the past few weeks, worrying investors about inflationary pressures. Hence, they are looking to forego riskier investments and avoid catching the proverbial falling knife stocks.…

Amesite (NASDAQ:AMST) stock is seeing massive movement on Friday despite a lack of news concerning the company. Source: fizkes / Shutterstock.com Here’s what to know about the strange trading for AMST stock today. So why are shares of the online learnings company on the rise? It likely has to do with retail traders on social…

Vertex Pharma (NASDAQ:VRTX) stock is dropping on Friday following the release of results from a Phase 2 clinical trial. Source: Shutterstock That trial was testing the effectiveness of VX-864. This is a possible treatment for patients suffering from alpha-1 antitrypsin deficiency (AATD) with the PiZZ genotype. According to the company, it saw statistical improvement from…

THE BARGAIN BIN 3 Cheap Stocks to Buy Even as Markets Hover Near All-Time Highs READ MORE Sponsored by Home / Today’s Market / Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday AMST and ORPH are leading our lists today By William White, InvestorPlace Writer Jun 11, 2021, 7:22 am EDT…